Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)
Protalix BioTherapeutics (PLX) recorded quarterly Notes Payables of $4.1 million in Q4 2020, down 4.98% quarter-over-quarter from $4.3 million in Q3 2020, and down 5.0% on a YoY basis from $4.3 million in Q1 2020.
Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020) Analysis & Trends
Protalix BioTherapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $4.1 million for Q4 2020.
- In Q4 2020, Notes Payables fell 5.0% year-over-year to $4.1 million; the TTM figure through Dec 2020 stood at $4.1 million (down 5.0% YoY), while the FY2020 annual figure was $4.1 million, down 5.0% from the prior year.
- Notes Payables was $4.1 million for Q4 2020 at Protalix BioTherapeutics, down from $4.3 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $4.3 million in Q4 2019 to a low of $4.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Protalix BioTherapeutics | 176.47 Mn | 165.67 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4.09 Mn |
| Sep 30, 2020 | 4.30 Mn |
| Jun 30, 2020 | 4.30 Mn |
| Mar 31, 2020 | 4.30 Mn |
| Dec 31, 2019 | 4.30 Mn |